Baricitinib vs Durvalumab

## Baricitinib vs Durvalumab: Overview

This comparison examines the pharmacological differences between **Baricitinib** and **Durvalumab**.

## Mechanism of Action

**Baricitinib**: Selective JAK1 and JAK2 inhibitor blocking cytokine signaling involved in inflammation.

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Baricitinib — 12 hours; Durvalumab — 17 days.

## Chemical Properties

**Molecular Formula**: Baricitinib — C16H17N7O2S; Durvalumab — N/A.

**Molecular Weight**: Baricitinib — 371.4170 g/mol; Durvalumab — N/A.

**Type**: Baricitinib — Small molecule; Durvalumab — Antibody.